<DOC>
	<DOC>NCT00339183</DOC>
	<brief_summary>The purpose of this study is to evaluate the treatment effect of panitumumab plus FOLFIRI compared to FOLFIRI alone as second line therapy for metastatic colorectal cancer.</brief_summary>
	<brief_title>Comparison of Treatment Effect of Chemotherapy With Panitumumab to Chemotherapy Alone</brief_title>
	<detailed_description />
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Antibodies, Monoclonal</mesh_term>
	<criteria>Man or woman at least 18 years old Diagnosis of metastatic colorectal cancer (mCRC) One and only one chemotherapy regimen for mCRC consisting of firstline 5FU based chemotherapy Radiologically documented disease progression per modified Response Evaluation Criteria in Solid Tumors (RECIST) criteria during treatment or within 6 months of last dose of firstline chemotherapy At least 1 unidimensionally measurable lesion of at least 20 mm per modified RECIST Eastern Cooperative Oncology Group (ECOG) status of 0, 1, or 2 Paraffinembedded tumor tissue from the primary tumor or metastasis available for central analyses Adequate hematologic, renal, and hepatic functions Negative pregnancy test within 72 hours of enrollment Other protocolspecified criteria may apply History of or known presence of central nervous system (CNS) metastases History of another primary cancer within 5 years of randomization Prior irinotecan therapy Prior antiepidermal growth factor receptor (EGFr) antibody therapy or treatment with small molecule EGFr inhibitors Any investigational agent or therapy within 30 days before randomization Known allergy or hypersensitivity to irinotecan, 5FU or leucovorin History of interstitial lung disease or evidence of interstitial lung disease on baseline chest computed tomography (CT) scan Active inflammatory bowel disease or other bowel disease causing chronic diarrhea Known positive tests for human immunodefiency virus (HIV), hepatitis C viris (HCV), acute or chronic active hepatitis B virus (HBV) Major surgery within 28 days of randomization or minor surgical procedure within 14 days of randomization Pregnant or breastfeeding Man or woman of childbearing potential not consenting to use adequate contraceptive methods or abstinence during the course of the study and for 6 months after last study drug administration (women) or 1 month after last study drug administration (men) Other protocolspecified criteria may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Oncology</keyword>
	<keyword>Cancer</keyword>
	<keyword>Metastatic Colorectal Cancer</keyword>
	<keyword>EGFr</keyword>
	<keyword>Panitumumab</keyword>
	<keyword>Clinical Trial</keyword>
	<keyword>Amgen</keyword>
</DOC>